Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Cai

Showing results (261-270 of 270) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 270 results.
Blood Advances|May 4, 2023
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemiaJoseph G W McCarter, David Nemirovsky, Christopher A Famulare, et al.
Nature|March 16, 2023
MEN1 mutations mediate clinical resistance to menin inhibitionFlorian Perner, Eytan M Stein, Daniela V Wenge, et al.
Leukemia & Lymphoma|September 3, 2021
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplantJan Philipp Bewersdorf, Andriy Derkach, Lohith Gowda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AMLJoshua F Zeidner, Tara L Lin, Rina Li Welkie, et al.
Cell Stem Cell|May 23, 2025
Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemiaMaria Sirenko, Soobeom Lee, Zhengxi Sun, et al.
Cancer Cell|November 12, 2024
In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancyRobert L Bowman, Andrew J Dunbar, Tanmay Mishra, et al.
Cancer Discovery|January 17, 2024
Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative NeoplasmsAndrew J Dunbar, Robert L Bowman, Young C Park, et al.
Blood Advances|October 23, 2023
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AMLSheng F Cai, Ying Huang, Jennie R Lance, et al.
American Journal of Hematology|October 17, 2022
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemiaMaximilian Stahl, Andriy Derkach, Noushin Farnoud, et al.
Journal of the National Cancer Institute|August 9, 2024
Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO)Kathryn H Schmitz, Justin C Brown, Melinda L Irwin, et al.
Pageof 27

Showing results (261-270 of 270) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 270 results.
Blood Advances|May 4, 2023
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemiaJoseph G W McCarter, David Nemirovsky, Christopher A Famulare, et al.
Nature|March 16, 2023
MEN1 mutations mediate clinical resistance to menin inhibitionFlorian Perner, Eytan M Stein, Daniela V Wenge, et al.
Leukemia & Lymphoma|September 3, 2021
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplantJan Philipp Bewersdorf, Andriy Derkach, Lohith Gowda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AMLJoshua F Zeidner, Tara L Lin, Rina Li Welkie, et al.
Cell Stem Cell|May 23, 2025
Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemiaMaria Sirenko, Soobeom Lee, Zhengxi Sun, et al.
Cancer Cell|November 12, 2024
In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancyRobert L Bowman, Andrew J Dunbar, Tanmay Mishra, et al.
Cancer Discovery|January 17, 2024
Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative NeoplasmsAndrew J Dunbar, Robert L Bowman, Young C Park, et al.
Blood Advances|October 23, 2023
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AMLSheng F Cai, Ying Huang, Jennie R Lance, et al.
American Journal of Hematology|October 17, 2022
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemiaMaximilian Stahl, Andriy Derkach, Noushin Farnoud, et al.
Journal of the National Cancer Institute|August 9, 2024
Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO)Kathryn H Schmitz, Justin C Brown, Melinda L Irwin, et al.
Pageof 27